Related Experiment Video
Updated: Feb 8, 2026
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
Immunomodulatory drugs in multiple myeloma
Maurizio Zangari1, Francesca Elice, Guido Tricot
1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. SandersToniJ@uams.edu
Immunomodulatory drugs (IMiDs) show potent anticancer effects against multiple myeloma (MM) by inhibiting tumor growth and stimulating immune responses. Clinical trials indicate significant patient responses with manageable toxicities, suggesting IMiDs as a promising MM treatment.
Area of Science:
- Pharmacology
- Immunology
- Oncology
Background:
- Immunomodulatory drugs (IMiDs) are analogs of thalidomide with anticancer properties.
- IMiDs exhibit potent antitumour effects on multiple myeloma (MM) cell lines in vitro.
- Their activity involves direct antiproliferative effects, anti-angiogenesis, cytokine inhibition, and T-cell stimulation.
Purpose of the Study:
- To evaluate the efficacy and toxicity of IMiDs in patients with multiple myeloma.
- To explore the mechanisms of action of IMiDs in MM treatment.
Main Methods:
- In vitro studies on MM cell lines.
- Clinical trials involving patients with progressive, refractory, or newly diagnosed MM.
- Assessment of treatment response and toxicity profiles.
Main Results:
- IMiDs demonstrated significant antitumour activity, with partial response rates ranging from 20% to 71%.
- Observed toxicities included thrombocytopenia, neutropenia, and cardiovascular events, with no significant neurotoxicity.
- The combination of IMiDs with dexamethasone may enhance therapeutic benefits.
Conclusions:
- IMiDs represent a promising therapeutic option for multiple myeloma patients.
- IMiDs offer a favorable efficacy and toxicity profile compared to parent compounds.
- Further investigation into IMiD combinations, such as with dexamethasone, is warranted.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015